Gene-edited TIL therapy for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new treatment called GC203 TIL, which uses your own immune cells (TILs) that have been gene-edited to fight pancreatic cancer. It is for people whose cancer has not responded to standard treatments and who are healthy enough to undergo this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have pancreatic ductal adenocarcinoma (a type of pancreatic cancer) that has been confirmed by a biopsy.
- Standard treatments for your cancer have stopped working, and you are willing to try a new therapy made from your own tumor cells.
- You must have at least one tumor that can be measured on scans.
- Your blood counts and organ function (kidney, liver) must be within certain limits.
- If you could have children, you must agree to use effective birth control for at least one year after the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a treatment called TIL therapy, which uses your own immune cells grown from a tumor sample, to treat advanced cancers of the liver/bile ducts or pancreas. It’s mainly for people whose standard treatments have already failed (or none exist), and who can safely provide tumor tissue for the cell preparation.
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
This early-phase study tests an experimental cell therapy made from your tumor’s immune cells (TILs) for advanced breast cancer. It may help shrink tumors or improve how long people stay in remission, but it’s still being studied for safety and effectiveness.
This early-phase study tests GC201 TIL therapy, made from your tumor’s immune cells (TILs), for advanced or returning gynecologic cancers. If standard treatments have already failed—or there aren’t standard options—this trial may offer a new way to train your immune system to fight the cancer.
This early-phase trial tests GC101 TIL, a treatment made from your own melanoma tumor cells, for advanced melanoma. It may help the immune system better fight the cancer after standard treatments have already stopped working or if none are available.
This trial tests a treatment that uses your own immune cells, called TILs, to fight advanced solid tumors. The cells are taken from a biopsy of your tumor, multiplied in a lab, and then given back to you. It might help if you have tried other treatments without success, or if no standard treatment is available.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.